-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33

Benzinga·07/14/2026 13:43:04
语音播报
JP Morgan analyst Jessica Fye maintains Aktis Oncology (NASDAQ:AKTS) with a Overweight and raises the price target from $30 to $33.